Successful Phase I Trial for ENERGI-F705PD
The Phase I trial of ENERGI-F705PD, a randomized, double-blind, placebo-controlled study, aimed to assess the safety, tolerability, and pharmacokinetics of this investigational drug among 24 healthy participants. The findings validated the drug’s favorable safety and tolerability profile while confirming the effectiveness of its sustained-release oral formulation. Energenesis Biomedical is now preparing to move forward with a Phase II trial.
Completion of Phase I Clinical Trial for Parkinson’s Disease Treatment
Energenesis Biomedical Co., Ltd. (TWSE: 6657), a biotechnology firm in the clinical stage specializing in therapies aimed at restoring cellular energy, has announced the successful completion of its Phase I clinical trial for ENERGI-F705PD. This oral investigational drug candidate targets Parkinson’s disease (PD). The trial’s results showcased positive safety and tolerability results among healthy volunteers, marking an important milestone in the drug’s development and reinforcing its potential as a disease-modifying treatment that addresses intracellular alpha-synuclein aggregation.
Plans for Phase II Clinical Trial Application
Energenesis Biomedical intends to submit an application for a Phase II clinical trial in 2025 to further explore the therapeutic effectiveness of ENERGI-F705PD in individuals diagnosed with Parkinson’s disease. “Existing treatments for Parkinson’s primarily alleviate symptoms, whereas ENERGI-F705PD introduces a groundbreaking therapeutic approach with the potential to modify the disease,” stated Dr. Han-Min Chen, CEO & Founder of Energenesis Biomedical. “By focusing on restoring cellular energy ATP levels, inhibiting alpha-synuclein aggregation, and lowering ROS levels for neuroprotection, this multifaceted strategy may significantly decelerate the progression of the disease. The promising outcomes from our Phase I trial bring us closer to providing a meaningful treatment for PD patients globally.”
Overview of ENERGI-F705PD
ENERGI-F705PD is an innovative small-molecule drug formulated for sustained oral release. Its design aims to boost cellular ATP and antioxidant production by utilizing the purine salvage, glycolysis, and pentose phosphate pathways. This comprehensive mechanism tackles crucial pathological features of Parkinson’s disease, such as:
– **Reduction and Prevention of Alpha-synuclein Aggregation:** Increased ATP functions as a hydrotrope, aiding in the prevention of misfolded alpha-synuclein aggregation, a significant pathogenic characteristic of PD.
– **Enhanced Antioxidant Capacity:** ENERGI-F705PD activates the pentose phosphate pathway (PPP), which results in greater NADPH production and improved cellular antioxidant defenses.
– **Boosting Tyrosine Hydroxylase Activity:** By optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD enhances the expression and function of tyrosine hydroxylase (TH), a critical enzyme involved in dopamine synthesis, thereby helping restore neurotransmitter levels in the brains of PD patients.
Potential of Targeting Alpha-Synuclein in Parkinson’s Disease
Parkinson’s disease, which afflicts over 10 million individuals worldwide, has no known cure at present, with current treatments primarily focused on symptom management. The buildup of alpha-synuclein protein is a defining feature of the disease, making it a highly attractive target for new disease-modifying therapies that aim to alter its course. There is substantial research and development underway in this vital area, encompassing both small molecules and antibody-based investigational treatments. ENERGI-F705PD, as an oral small-molecule drug, offers distinct advantages over antibody therapies, including superior ability to penetrate the blood-brain barrier, convenient oral administration, direct targeting within cells, and potentially easier manufacturing processes.
About Energenesis Biomedical
Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a biopharmaceutical company in the clinical stage committed to creating innovative therapies that restore cellular energy and activate intrinsic repair processes. By merging proprietary small-molecule innovation with AI-driven drug repurposing, Energenesis Biomedical aspires to expedite the development of treatments for unmet medical needs across various therapeutic domains, including neurodegenerative diseases, chronic wounds, and rare disorders. The company’s leading candidates include:
– **ENERGI-F705PD:** Tablet for Parkinson’s disease (Preparing for Phase II)
– **ENERGI-F703DFU:** Gel for diabetic foot ulcers (Phase III)
– **ENERGI-F701:** Tonic for alopecia (Phase II completed)
– **ENERGI-F703EB:** Cream for epidermolysis bullosa (EB), granted FDA Orphan Drug and Rare Pediatric Disease designations, and EMA orphan designation (Preparing for Phase II)
